Your browser doesn't support javascript.
loading
CCR5 inhibition in critical COVID-19 patients decreases inflammatory cytokines, increases CD8 T-cells, and decreases SARS-CoV2 RNA in plasma by day 14.
Patterson, Bruce K; Seethamraju, Harish; Dhody, Kush; Corley, Michael J; Kazempour, Kazem; Lalezari, Jay; Pang, Alina P S; Sugai, Christopher; Mahyari, Eisa; Francisco, Edgar B; Pise, Amruta; Rodrigues, Hallison; Wu, Helen L; Webb, Gabriela M; Park, Byung S; Kelly, Scott; Pourhassan, Nader; Lelic, Alina; Kdouh, Lama; Herrera, Monica; Hall, Eric; Bimber, Benjamin N; Plassmeyer, Matthew; Gupta, Raavi; Alpan, Oral; O'Halloran, Jane A; Mudd, Philip A; Akalin, Enver; Ndhlovu, Lishomwa C; Sacha, Jonah B.
Afiliação
  • Patterson BK; IncellDX, Menlo Park, CA, USA. Electronic address: brucep@incelldx.com.
  • Seethamraju H; Montefiore Medical Center, New York, NY, USA.
  • Dhody K; Amarex Clinical Research LLC, Germantown, MD, USA.
  • Corley MJ; Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine, New York, NY, USA.
  • Kazempour K; Amarex Clinical Research LLC, Germantown, MD, USA.
  • Lalezari J; Quest Clinical Research, San Francisco, CA, USA.
  • Pang APS; Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine, New York, NY, USA.
  • Sugai C; University of Hawaii, Honolulu, HI, USA.
  • Mahyari E; Vaccine & Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Portland, OR, USA.
  • Francisco EB; IncellDX, Menlo Park, CA, USA.
  • Pise A; IncellDX, Menlo Park, CA, USA.
  • Rodrigues H; IncellDX, Menlo Park, CA, USA.
  • Wu HL; Vaccine & Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Portland, OR, USA.
  • Webb GM; Vaccine & Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Portland, OR, USA.
  • Park BS; Vaccine & Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Portland, OR, USA.
  • Kelly S; CytoDyn Inc., Vancouver, WA, USA.
  • Pourhassan N; CytoDyn Inc., Vancouver, WA, USA.
  • Lelic A; Beckman Coulter, Miami, FL, USA.
  • Kdouh L; Beckman Coulter, Miami, FL, USA.
  • Herrera M; Bio-Rad, Pleasanton, CA, USA.
  • Hall E; Bio-Rad, Pleasanton, CA, USA.
  • Bimber BN; Vaccine & Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Portland, OR, USA.
  • Plassmeyer M; Amerimmune LLC, Fairfax, VA, USA.
  • Gupta R; State University of New York-University Hospital of Brooklyn, NY, USA.
  • Alpan O; Amerimmune LLC, Fairfax, VA, USA.
  • O'Halloran JA; Division of Infectious Diseases, Department of Internal Medicine, USA.
  • Mudd PA; Department of Emergency Medicine, Washington University in Saint Louis School of Medicine, Saint Louis, MO, USA.
  • Akalin E; Montefiore Medical Center, New York, NY, USA.
  • Ndhlovu LC; Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine, New York, NY, USA.
  • Sacha JB; Vaccine & Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Portland, OR, USA.
Int J Infect Dis ; 103: 25-32, 2021 Feb.
Article em En | MEDLINE | ID: mdl-33186704

Texto completo: 1 Base de dados: MEDLINE Assunto principal: RNA Viral / Citocinas / Linfócitos T CD8-Positivos / Antagonistas dos Receptores CCR5 / SARS-CoV-2 / Tratamento Farmacológico da COVID-19 Tipo de estudo: Clinical_trials Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: RNA Viral / Citocinas / Linfócitos T CD8-Positivos / Antagonistas dos Receptores CCR5 / SARS-CoV-2 / Tratamento Farmacológico da COVID-19 Tipo de estudo: Clinical_trials Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2021 Tipo de documento: Article